← Dashboard
Sep 19, 2026 12:37 AM ET
Signal
FDA/Bio
TAKEDA PHARMACEUTICAL (TAK) GETS PRIORITY REVIEW. CAN ZASOCITINIB WIN IN PSORIASIS? - YAHOO
Priority review for zasocitinib in psoriasis signals potential regulatory catalyst.
What changed
Priority review for zasocitinib in psoriasis signals potential regulatory catalyst.
Why it matters
Priority review for zasocitinib in psoriasis signals potential regulatory catalyst. — impact context not separately stored; see What changed.
Sources
yahoo
Related signals
In reversal, American Cancer Society urges routine prostate cancer screening →
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →
PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →